CRT, ArcticDx combine in cancer risk tech pact
This article was originally published in Clinica
Executive Summary
London, UK-based oncology specialist Cancer Research Technology (CRT) has teamed up with Canadian molecular testing firm ArcticDx in a licensing agreement for the latter’s Colo Risk test for colorectal cancer. The non-exclusive agreement will see results from genome-wide Cancer Research UK-funded studies integrated into ArcticDx’s risk assessment technology. The aim is to help healthcare professionals assess patients who might be at a higher risk of developing bowel cancer, so they may receive specific individual treatment. Toronto, Ontario-based ArcticDx will make an upfront payment to CRT, which will also receive royalties form sales of the Colo Risk test.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals